The University of Chicago Header Logo

Connection

Mary Rinella to Liver Cirrhosis

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Liver Cirrhosis.
Mary Rinella
Connection Strength
6.201
Liver Cirrhosis
  1. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.587
  2. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. Obstet Gynecol. 2017 06; 129(6):1118-1123.
    View in: PubMed
    Score: 0.507
  3. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.504
  4. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.343
  5. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.202
  6. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689.
    View in: PubMed
    Score: 0.196
  7. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 Dec 01; 78(6):E103-E104.
    View in: PubMed
    Score: 0.192
  8. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
    View in: PubMed
    Score: 0.189
  9. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
    View in: PubMed
    Score: 0.189
  10. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022 Jul 10; 22(1):335.
    View in: PubMed
    Score: 0.181
  11. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
    View in: PubMed
    Score: 0.176
  12. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022 01 27; 73:529-544.
    View in: PubMed
    Score: 0.173
  13. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.173
  14. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.169
  15. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.169
  16. Non-alcoholic fatty liver disease. Lancet. 2021 06 05; 397(10290):2212-2224.
    View in: PubMed
    Score: 0.166
  17. Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation. Dig Dis Sci. 2021 01; 66(1):7-9.
    View in: PubMed
    Score: 0.163
  18. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
    View in: PubMed
    Score: 0.159
  19. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 05; 19(5):1020-1029.e7.
    View in: PubMed
    Score: 0.157
  20. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol. 2020 07; 73(1):9-11.
    View in: PubMed
    Score: 0.155
  21. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
    View in: PubMed
    Score: 0.151
  22. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.150
  23. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
    View in: PubMed
    Score: 0.150
  24. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci. 2019 12; 64(12):3413-3430.
    View in: PubMed
    Score: 0.147
  25. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
    View in: PubMed
    Score: 0.146
  26. Editorial: sarcopenia in liver transplantation-our weakest patients may need the strongest push. Aliment Pharmacol Ther. 2019 04; 49(8):1100-1101.
    View in: PubMed
    Score: 0.144
  27. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.137
  28. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228.
    View in: PubMed
    Score: 0.050
  29. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91.
    View in: PubMed
    Score: 0.050
  30. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003 Jul; 58(1):122-7.
    View in: PubMed
    Score: 0.048
  31. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024.
    View in: PubMed
    Score: 0.048
  32. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.
    View in: PubMed
    Score: 0.044
  33. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
    View in: PubMed
    Score: 0.042
  34. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
    View in: PubMed
    Score: 0.040
  35. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
    View in: PubMed
    Score: 0.039
  36. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703.
    View in: PubMed
    Score: 0.035
  37. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.